VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Black on the Developments in the Field of Immunotherapy for Bladder Cancer

Peter Black, MD
Published: Friday, Aug 25, 2017



Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.

Immunotherapy still holds the majority of interest in bladder cancer, but there is more to treatments than just immunotherapy, states Black.

The clinical trial field has become very complex as things move upstream, explains Black. There are adjuvant trials before and after radical cystectomy, and trials in non-muscle invasive bladder cancer.



Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.

Immunotherapy still holds the majority of interest in bladder cancer, but there is more to treatments than just immunotherapy, states Black.

The clinical trial field has become very complex as things move upstream, explains Black. There are adjuvant trials before and after radical cystectomy, and trials in non-muscle invasive bladder cancer.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x